NCT04406831Recruiting
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 22 May 2020
- Start date
- Apr 2015
- Primary completion date
- Apr 2030
- Lead sponsor
- Nuvance Health
- Diseases
- Pancreatic cancer
- NCT number
- NCT04406831
What you commit to
- Study type: Observational
- Planned participants: 200
- From Apr 2015 to the primary completion date, Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having received prior anti-cancer treatments for metastatic pancreatic cancer
- Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
- Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable
Who the study is looking for
- Have biopsy proven adenocarcinoma of the pancreas
- Have initially inoperable disease, classified as either locally advanced or metastatic disease
- Recurrent disease after a Whipple procedure is allowed
- Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
- Have radiographically measurable disease
- Have an ECOG performance status of 2 or less
- Be willing to contribute the required information and specimens
- Provide written signed consent to participate
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuvance Health Coordinator of this site? Confirm its status | Norwalk | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.